| NCT ID | NCT07217782 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington University School of Medicine |
| Condition | Juvenile Idiopathic Arthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2025-09-15 |
| Primary Completion | 2030-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 140 participants in total. It began in 2025-09-15 with a primary completion date of 2030-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Juvenile idiopathic arthritis (JIA) is the most common rheumatologic disease in children. The main symptoms of JIA, which are often the primary focus of treatment, include joint swelling, stiffness, and tenderness. Additional symptoms can include malaise, fatigue, and pain. However, the exact mechanisms contributing to pain are not yet fully understood. Participants will complete a 2.5-hours study session. In the study session, psychophysical assessments of thermal and pressure stimuli will be performed. In addition, demographic, social, pubertal maturation, and behavioral and psychological factors will be collected via questionnaires. A saliva sample and/or blood draw may occur for the analysis of various immune factors and sex hormones. If a joint aspiration is done as part of their standard of care, we will request a sample of the synovial fluid for analyses of immune, hormonal and/or genetic factors. Participants will have the option to participate in additional optional follow-up study visits (every 3 months, up to 1 year) and to complete monthly surveys asking about their juvenile arthritis.
Eligibility Criteria
Inclusion Criteria: 1. Age between 9-17 2. Males and females 3. English speakers 4. Able to complete surveys and understand study instructions 5. Juvenile arthritis group: diagnosed or suspected of juvenile arthritis 6. Control group: healthy Exclusion Criteria: 1. Pregnancy or breastfeeding 2. (Control Group) Diagnosed with a chronic pain condition 3. (Control Group) Diagnosed with psychiatric condition including ADHD, anxiety, depression, etc.
Contact & Investigator
Hadas Nahman-Averbuch, PhD
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT07217782 clinical trial?
This trial is open to participants of all sexes, aged 9 Years or older, up to 17 Years, studying Juvenile Idiopathic Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07217782 currently recruiting?
Yes, NCT07217782 is actively recruiting participants. Contact the research team at painlab@wustl.edu for enrollment information.
Where is the NCT07217782 trial being conducted?
This trial is being conducted at St Louis, United States.
Who is sponsoring the NCT07217782 clinical trial?
NCT07217782 is sponsored by Washington University School of Medicine. The principal investigator is Hadas Nahman-Averbuch, PhD at Washington University School of Medicine. The trial plans to enroll 140 participants.